According to the World Health Organization, over the past decade, oncological diseases have remained a leading cause of morbidity and mortality world- wide. The article examines the role of serum matrix metalloproteinase-7 (MMP-7), MMP-9, and cysteine-rich angiogenic inducer 61 (CYR61) in the early diagnosis of breast cancer (BC). This research encompasses data from 74 women, aged 30-51, diagnosed with BC who visited the National Oncology Centre during 2023-2024. A control group consisted of 15 healthy women aged 25-38. Histochemical analysis determined the BC biotypes: 8 participants exhibited a “triple-negative” phenotype, 33 were Her2-positive, and 33 were Her2-negative. The control results were compared with both the collective data from all BC cases and specific subgroup indicators by biotype. The study found no statistically significant variation in biomarker levels across Her2-positive, Her2-negative, and triple-negative BC subgroups. However, significant differences in MMP-9 and CYR-61 levels were detected between the overall BC group and the control group (p<0.001). The study suggests that while serum biomarker levels do not differ significantly between BC biotypes based on Her2 secretion, the serum levels of MMP-9 and CYR-61 could be utilized as essential laboratory biomarkers for BC diagnosis irrespective of biotype.